A mouse with humanized liver as an animal model for predicting drug effects and for studying hepatic viral infection: Where to next

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 11, 2013, Pages 1419-1435

  Yoshizato, Katsutoshi ^a   Tateno, Chise ^a  

^a PhoenixBio USA Corporation   (Japan)

Author keywords

Chimeric mouse; Drug testing; Hepatitis infection model; Mouse with humanized liver

Indexed keywords

BIOTECHNOLOGY; CHIMERA; DISEASE MODEL; DRUG RESEARCH; DRUG SCREENING; IMMUNOCOMPETENT CELL; LIVER; LIVER CELL; MOUSE MODEL; NONHUMAN; PLURIPOTENT STEM CELL; REVIEW; VIRUS HEPATITIS;

ANIMALS; CELL PROLIFERATION; CHIMERA; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HEPATITIS, VIRAL, HUMAN; HEPATOCYTES; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LIVER; LIVER DISEASES; MICE; RATS;

EID: 84886032103     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.826649     Document Type: Review

References (94)

1. Hyodo K, Yamamoto E, Suzuki T, et al. Development of liposomal anticancer drugs. Biol Pharm Bull 2013;36(5):703-7
2. Sun H, Xia M, Austin CP, Huang R. Paradigm shift in toxicity testing and modeling. AAPS J 2012;14(3):473-80
3. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates Nat Rev Drug Discov 2004;3:711-15 (Pubitemid 39173511)
4. Dr. Sugai, Sinpersonal communication
5. Renaud HJ, Cui JY, Khan M, Klaassen CD. Tissue distribution and gender-divergent expression of 78 cytochrome P450 mRNAs in mice. Toxicol Sci 2011;124:261-77
6. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005;352:2211-21; Review
7. Jiang XL, Gonzalez FJ, Yu AM. Drug-metabolizing enzyme, transporter, and nuclear receptor genetically modified mouse models. Drug Metab Rev 2011;43:27-40
8. Liggett SB. Genetically modified mouse models for pharmacogenomic research. Nat Rev Genet 2004;5:657-63; Review (Pubitemid 39150122)
9. Muruganandan S, Sinal CJ. Mice as clinically relevant models for the study of cytochrome P450-dependent metabolism. Clin Pharmacol Ther 2008;83:818-28 (Pubitemid 351704925)
10. Dandri M, Burda MR, Torok E, et al. Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology 2001;33:981-8
11. Mercer DF, Schiller DE, Elliott JF, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001;7:927-33 (Pubitemid 32756430)
12. Tateno C, Yoshizane Y, Saito N, et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 2004;165:901-12 (Pubitemid 39129297)
13. Yoshizato K, Tateno C. In vivo modeling of human liver for pharmacological study using humanized mouse. Expert Opin Drug Metab Toxicol 2009;5:1435-46; Review
14. Yoshizato K, Tateno C, Utoh R. The mechanism of liver size control in mammals: a novel animal study. Int J Des Nature Ecodynamics 2009;4:123-42
15. Yoshizato K, Tateno C. A human hepatocyte-bearing mouse: an animal model to predict drug metabolism and effectiveness in humans. PPAR Res 2009;2009:476217
16. Yoshizato K, Tateno C, Utoh R. Mice with liver composed of human hepatocytes as an animal model for drug testing. Curr Drug Discov Technol 2012;9(1):63-76
17. Sandgren EP, Degen JL, Palmiter RD, et al. Replacement of diseased mouse liver by hepatic cell transplantation. Science 1994;263:1149-52 (Pubitemid 24105963)
18. Bosma GC, Custer RP, Bosma MJ. A severe combined immunodeficiency mutation in the mouse. Nature 1983;301:527-30 (Pubitemid 13160576)
19. Schatz DG. Antigen receptor genes and the evolution of a recombinase. Semin Immunol 2004;16:245-56 (Pubitemid 39445623)
20. Azuma H, Paulk N, Ranade A, et al. Robust expansion of human hepatocytes in Fah(-/-)/Rag2(-/-)/Il2rg(-/-) mice. Nat Biotechnol 2007;25:903-10 (Pubitemid 47236918)
21. Traggiai E, Chicha L, Mazzucchelli L, et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 2004;304:104-7 (Pubitemid 38451466)
22. Gorantla S, Sneller H, Walters L, et al. Human immunodeficiency virus type 1 pathobiology studied in humanized BALB/c-Rag2-/-gammac-/-mice. J Virol 2007;81:2700-12 (Pubitemid 46447035)
23. Shinkai Y, Rathbun G, Lam KP, et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 1992;68:855-67
24. Perryman LE. Molecular pathology of severe combined immunodeficiency in mice, horses, and dogs. Vet Pathol 2004;41:95-100 (Pubitemid 38453181)
25. Bosma MJ, Carroll AM. The SCID mouse mutant: definition, characterization, and potential uses. Annu Rev Immunol 1991;9:323-50; Review
26. Suemizu H, Hasegawa M, Kawai K, et al. Establishment of a humanized model of liver using NOD/Shi-scid IL2Rgnull mice. Biochem Biophys Res Commun 2008;377:248-52
27. Kikutani H, Makino S. The murine autoimmune diabetes model: NOD and related strains. Adv Immunol 1992;51:285-322
28. Ohbo K, Suda T, Hashiyama M, et al. Modulation of hematopoiesis in mice with a truncated mutant of the interleukin-2 receptor gamma chain. Blood 1996;87:956-67 (Pubitemid 26043526)
29. Heckel JL, Sandgren EP, Dege JL, et al. Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator. Cell 1990;62:447-56
30. Mohammed FF, Pennington CJ, Kassiri Z, et al. Metalloproteinase inhibitor TIMP-1 affects hepatocyte cell cycle via HGF activation in murine liver regeneration. Hepatology 2005;41:857-67 (Pubitemid 40462949)
31. Bissig KD, Le TT, Woods NB, Verma IM. Repopulation of adult and neonatal mice with human hepatocytes: a chimeric animal model. Proc Natl Acad Sci USA 2007;104:20507-11
32. Grompe M, et al. Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. Genes Dev 1993;7:2298-307 (Pubitemid 24003234)
33. Brezillon NM, DaSilva L, L'Hôte D, et al. Rescue of fertility in homozygous mice for the urokinase plasminogen activator transgene by the transplantation of mouse hepatocytes. Cell Transplant 2008;17:803-12
34. Sandgren EP, Palmiter RD, Heckel JL, et al. Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene. Cell 1991;66:245-56 (Pubitemid 121001363)
35. Okamura K, Asahina K, Fujimori H, et al. Generation of hybrid hepatocytes by cell fusion from monkey embryoid body cells in the injured mouse liver. Histochem Cell Biol 2006;125:247-57 (Pubitemid 43228198)
36. Tateno C, Miya F, Wake K, et al. Morphological and microarray analyses of human hepatocytes from xenogeneic host livers. Lab Invest 2013;93(1):54-71
37. Lootens L, Meuleman P, Pozo OJ, et al. uPA+/+-SCID mouse with humanized liver as a model for in vivo metabolism of exogenous steroids: methandienone as a case study. Clin Chem 2009;55:1783-93
38. Okumura H, Katoh M, Sawada T, et al. Humanization of excretory pathway in chimeric mice with humanized liver. Toxicol Sci 2007;97:533-8 (Pubitemid 47073867)
39. Botrè F. Humanized animal models to study drug metabolism: no longer a "chimera" Clin Chem 2009;55(10):1763-4
40. Lootens L, Van Eenoo P, Meuleman P, et al. The uPA(+/+)-SCID mouse with humanized liver as a model for in vivo metabolism of 4-androstene-3,17-dione. Drug Metab Dispos 2009;37:2367-74
41. Dai Y, Su W, Ding Z, et al. Mehta JL. Regulation of MSR-1 and CD36 in macrophages by LOX-1 mediated through PPAR-g. Biochem Biophys Res Commun 2013; [Epub ahead of print]
42. Schulz-Utermoehl T, Sarda S, Foster JR, et al. Evaluation of the pharmacokinetics, biotransformation and hepatic transporter effects of troglitazone in mice with humanized livers. Xenobiotica 2012;42(6):503-17
43. Sanoh S, Horiguchi A, Sugihara K, et al. Predictability of metabolism of ibuprofen and naproxen using chimeric mice with human hepatocytes. Drug Metab Dispos 2012;40(12):2267-72
44. Sanoh S, Horiguchi A, Sugihara K, et al. Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver. Drug Metab Dispos 2012;40(2):322-8
45. Garattini E, Mendel R, Romão MJ, et al. Mammalian molybdo-flavoenzymes, an expanding family of proteins: structure, genetics, regulation, function and pathophysiology. Biochem J 2003;372(Pt 1):15-32; Review (Pubitemid 36609603)
46. Sanoh S, Nozaki K, Murai H, et al. Prediction of human metabolism of FK3453 by aldehyde oxidase using chimeric mice transplanted with human or rat hepatocytes. Drug Metab Dispos 2012;40(1):76-82
47. Pryde DC, Dalvie D, Hu Q, et al. Aldehyde oxidase: an enzyme of emerging importance in drug discovery. J Med Chem 2010;53:8441-60
48. Garattini E, Terao M. Increasing recognition of the importance of aldehyde oxidase in drug development and discovery. Drug Metab Rev 2011;43:374-86
49. Akabane T, Tanaka K, Irie M, et al. Case report of extensive metabolism by aldehyde oxidase in humans: pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans. Xenobiotica 2011;41:372-84
50. Brunner C, Muller B, Wirth T. Bruton's tyrosine kinase is involved in innate and adaptive immunity. Histol Histopathol 2005;20:945-55 (Pubitemid 40932612)
51. Pan Z. Bruton's tyrosine kinase as a drug discovery target. Drug News Perspect 2008;21:357-62
52. Liu L, Di Paolo J, Barbosa J, et al. Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy. J Pharmacol Exp Ther 2011;338:154-63
53. Liu L, Halladay JS, Shin Y, et al. Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor. Drug Metab Dispos 2011;39(10):1840-9
54. Ploss A, Rice CM. Towards a small animal model for hepatitis C. EMBO Rep 2009;10:1220-7
55. Uprichard SL, Chung J, Chisari FV, Wakita T. Replication of a hepatitis C virus replicon clone in mouse cells. Virol J 2006;3:89
56. Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005;11:791-6 (Pubitemid 41021213)
57. Bissig KD, Wieland SF, Tran P, et al. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest 2010;120:924-30
58. Tsuge M, Hiraga N, Takaishi H, et al. Yoshizato K. nfection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology 2005;42(5):1046-54 (Pubitemid 43112671)
59. Kimura T, Imamura M, Hiraga N, et al. Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice. J Gen Virol 2008;89(Pt 9):2108-13
60. Kamiya N, Iwao E, Hiraga N, et al. Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor. J Gen Virol 2010;91(Pt 7):1668-77
61. Ohara E, Hiraga N, Imamura M, et al. Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice. J Hepatol 2011;54(5):872-8
62. Abe H, Imamura M, Hiraga N, et al. ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo. J Hepatol 2011;55(1):11-18
63. Perni RB, Almquist SJ, Byrn RA, et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 2006;50:899-909 (Pubitemid 43327793)
64. Hiraga N, Imamura M, Abe H, et al. Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo. Hepatology 2011;54(3):781-8
65. Song X, Guo Y, Duo S, et al. A mouse model of inducible liver injury caused by tet-on regulated urokinase for studies of hepatocyte transplantation. Am J Pathol 2009;175:1975-83
66. Held WA, Mullins JJ, Kuhn NJ, et al. T antigen expression and tumorigenesis in transgenic mice containing a mouse major urinary protein/SV40 T antigen hybrid gene. EMBO J 1989;8:183-91 (Pubitemid 19273961)
67. Weglarz TC, Degen JL, Sandgren EP. Hepatocyte transplantation into diseased mouse liver. Kinetics of parenchymal repopulation and identification of the proliferative capacity of tetraploid and octaploid hepatocytes. Am J Pathol 2000;157:1963-74
68. He Z, Zhang H, Zhang X, et al. Liver xeno-repopulation with human hepatocytes in Fah-/-Rag2-/-mice after pharmacological immunosuppression. Am J Pathol 2010;177:1311-19
69. Escribano O, Fernández-Moreno MD, Piña MJ, et al. Pretreatment with FK506 up-regulates insulin receptors in regenerating rat liver. Hepatology 2002;36:555-61 (Pubitemid 34977165)
70. Legrand N, Ploss A, Balling R, et al. Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe 2009;6:5-9; Review
71. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005;436:946-52; Review (Pubitemid 41191670)
72. Washburn ML, Bility MT, Zhang L, et al. A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology 2011;140:1334-44
73. Di Stasi A, Tey SK, Dotti G, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011;365(18):1673-83
74. Pajvani UB, Trujillo ME, Combs TP, et al. Fat apoptosis through targeted activation of caspase 8: a new mouse model of inducible and reversible lipoatrophy. Nat Med 2005;11:797-803 (Pubitemid 41021214)
75. Robinet E, Baumert TF. A first step towards a mouse model for hepatitis C virus infection containing a human immune system. J Hepatol 2011;55:718-20
76. Bataller R, Paik YH, Lindquist JN, et al. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 2004;126:529-40 (Pubitemid 38182310)
77. Utoh R, Tateno C, Kataoka M, et al. Hepatic hyperplasia associated with discordant xenogeneic parenchymal-nonparenchymal interactions in human hepatocyte-repopulated mice. Am J Pathol 2010;177:654-65
78. Tsuge M, Fujimoto Y, Hiraga N, et al. Hepatitis C virus infection suppresses the interferon response in the liver of the human hepatocyte chimeric mouse. PLoS ONE 2011;6(8):e23856
79. Okazaki A, Hiraga N, Imamura M, et al. Severe necroinflammatory reaction caused by natural killer cell-mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse. Hepatology 2012;56:555-66
80. Turrini P, Monego G, Gonzalez J, et al. Human hepatocytes in mice receiving]g pre-immune injection with human cord blood cells. Biochem Biophys Res Commun 2005;326(1):66-73
81. Cruse JM, Lewis RE Jr. The immune system victorious: selective preservation of self. Immunol Res 1993;12(2):101-14; Review (Pubitemid 23285735)
82. Porteus MH, Carroll D. Gene targeting using zinc finger nucleases. Nat Biotechnol 2005;23(8):967-73 (Pubitemid 41114030)
83. Geurts AM, Cost GJ, Freyvert Y, et al. Knockout rats via embryo microinjection of zinc-finger nucleases. Science 2009;325(5939):433
84. Mashimo T, Takizawa A, Kobayashi J, et al. Generation and characterization of severe combined immunodeficiency rats. Cell Rep 2012;2(3):685-94
85. Katayama S, Tateno C, Asahara T, Yoshizato K. Size-dependent in vivo growth potential of adult rat hepatocytes. Am J Pathol 2001;158(1):97-105 (Pubitemid 32096475)
86. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126(4):663-76 (Pubitemid 44233629)
87. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318(5858):1917-20
88. Si-Tayeb K, Noto FK, Nagaoka M, et al. Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology 2010;51(1):297-305
89. Takayama K, Inamura M, Kawabata K, et al. Generation of metabolically functioning hepatocytes from human pluripotent stem cells by FOXA2 and HNF1alpha transduction. J Hepatol 2012;57(3):628-36
90. Schwartz RE, Trehan K, Andrus L, et al. Modeling hepatitis C virus infection using human induced pluripotent stem cells. Proc Natl Acad Sci USA 2012;109(7):2544-8
91. Wu X, Robotham JM, Lee E, et al. Productive hepatitis C virus infection of stem cell-derived hepatocytes reveals a critical transition to viral permissiveness during differentiation. PLoS Pathog 2012;8(4):e1002617
92. Marukian S, Andrus L, Sheahan TP, et al. Hepatitis C virus induces interferon-l and interferon-stimulated genes in primary liver cultures. Hepatology 2011;54(6):1913-23
93. Espejel S, Roll GR, McLaughlin KJ, et al. Induced pluripotent stem cell-derived hepatocytes have the functional and proliferative capabilities needed for liver regeneration in mice. J Clin Invest 2010;120(9):3120-6
94. Grompe M, Lindstedt S, al-Dhalimy M, et al. Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. Nat Genet 1995;10(4):453-60